UK Industry Body Finds Sanofi in Breach Over RSV Therapy Claims Against Pfizer
A UK pharmaceutical industry watchdog has ruled that Sanofi breached the country’s code of practice by making misleading claims about its respiratory syncytial virus (RSV) therapy in comparison with a rival product from Pfizer.
Prescription Medicines Code Of Practice Authority | 04/02/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy